12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eliquis apixaban regulatory update

Bristol-Myers and Pfizer said FDA accepted a resubmitted NDA for Eliquis apixaban to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The new PDUFA date is March 17, 2013. Bristol-Myers...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >